CharlesHarmonPierceMDPhD, FCP, CPI

Addiction Medicine, Urgent Care, Clinical Pharmacology

Medical Director at the Pax Treatment Centers (addiction Rx), in Middletown, Ohio - and - Medical Director, Deaconess Mobile Health Check, 625 Elismore Place, Ste 900, Cincinnati OH 45202

Join to view full profile

Dr. Pierce is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pierce's full profile

Already have an account?

Office
3645 Stonecreek Blvd
Unit D
Cincinnati, OH 45251
Phone+1 513-429-4903

Fax+1 513-923-2301

Summary

Charles H Pierce, MD, PhD, FCP, CPI

From an original Master’s thesis (Pharmacology) in 1961 (Minnesota) through a Doctorate in Surgery-Pharmacology in 1974 (Saskatchewan) and continuing throughout 48+ years in the practice of clinical medicine as a family physician (7 years as an ER doc) and 27+ years in the medical research industry (7 years as a Principal Investigator), Charles has an experienced based knowledge of the Clinical Research part of Drug Development.

He is an APPI/APCR Certified Principal Investigator (CPI in 2003 and recertification’s to 2018). He is frequently actively involved in Webinars, courses and workshops giving the clinical investigator and staff an understanding and appreciation of the ethics as well as the science and regulations governing clinical research with drugs or devices. The end must be knowledge and keen observation to ensure drug safety.
Charles’ active management experience in the medical research industry gives him first-hand practical experience and knowledge to develop Phase I, IIa confined study Clinical Pharmacology Units (CPU’s). From experience and practical know-how the special needs of these units (from the floor plans to operational SOPs) has been of added value to those considering this venture. He has work experience in Device Studies and Pharmacovigilance. The later (PV) is of special interest as Phase I through Phase III do not guarantee drug safety. Actually this vigilance must start with the very first studies in human subjects.
Charles is a Fellow and Life Member of the American Academy of Family Physicians and Emeritus fellow of the American College of Clinical Pharmacology (ACCP) of which he was a Regent 1995-2000, Chairman of the 2001 annual meeting, and the 2004 recipient of the Nathaniel Kwitt Distinguished Service Award. He is an active member of the Association of Clinical Pharmacology Units (ACPU) of which he was a trustee (2007-2011) and chaired the successful 2010 annual meeting. .....

Education & Training

University of SaskatchewanPh.D., Surgery, 1974
McGill UniversityPh.D., 1971 - 1973
University Saskatchewan Royal HospitalTransitional Year, 1968 - 1969
University Saskatchewan Royal HospitalClass of 1968
University of SaskatchewanClass of 1968
University of MinnesotaM.Sc., Pharmacology, 1961
University of MinnesotaB.A., 1956

Certifications & Licensure

OH State Medical License 2003 - 2026
OH State Medical License 2003 - 2026
MN State Medical License 1972 - 2003
VT State Medical License 1985 - 1990
AL State Medical License 1974 - 1974
ACRPCertified Principal Investigator

Awards, Honors, & Recognition

Nathaniel T. Kwit Distinguished Service Award American College of Clinical Pharmacology, 2004
Paul Harris Fellow Rotary Club of Lincoln, NE, 1999
Rotarian of the Year Rotary Club of Westmount (Quebec), 1990
Fellow American Academy of Family Physicians, 1988
Rotarian of the Year Rotary Club of Burlington (Vermont), 1987
Fellow American College of Clinical Pharmacology, 1974
Research Fellow Canadian Heart Foundation, 1969
Sigma Delta Psi - National Honorary Athletic Fraternity 1957
Theta Delta Chi Academic Fraternity
Join now to see all

Clinical Trials

Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder Start of enrollment: 2009 Jan 01
Completed
Phase 1

Publications & Presentations

Journal Articles

The Pre-Menstrual Syndrome is Treatable
Pierce, C.H., J Trop Dis, 4/1/2016
Drug-Induced Liver Injury Continues to Haunt Drug Development: Why is this Still a Problem and How to Identify it
Pierce, C.H., Monitor, 1/1/2014
Subject Recruitment: Are You Prepared To Succeed?
Metzner, M., Pierce, C.H., Monitor, 1/1/2013
The Challenges of Conducting Studies in the Early Clinical Development period (Phase I and IIa)
Pierce, C.H., Dorozinsky, D.W., Monitor, 1/1/2012
The New Status of Physician Investigator Certification
Pierce, C.H., Monitor, 1/1/2012
Importance of Data and Safety Monitoring in Clinical Research
Pierce, C.H., Monitor, 1/1/2012
Common GCP Violations and Site Mistakes: How to Avoid them
Pierce, C.H., Monitor, 1/1/2012
ACPU Guidance and Recommendations for the Operation of Clinical Pharmacology Units
Dorozinsky, D.W., Pierce, C.H., Lavin, C, Turik, M,A., Greenberg, H.E., Monitor, 1/1/2012
Certification: A Smart Move for Investigators
Pierce, C.H., GCPj, 1/1/2012
Investigator Responsibilities in Clinical Research: ICH Viewpoint
Pierce, C.H., Greenberg, H.E., Monitor, 1/1/2011
The American Academy of Pharmaceutical Physicians is…
Pierce, C.H., Clinical Researcher, 1/1/2004
Where are the Pediatric Investigators?
Pierce, C.H., Walson, P., GCPj, 1/1/2002
Are new drugs really riskier?
Pierce, C.H., GCPj, 1/1/2002
Human subject safety
Pierce, C.H., GCPj, 1/1/2001
Asthma Therapy from the Practice perspective: Changes in the Wind
Pierce, C.H., Journal of Clinical Pharmacology, 1/1/1999
How calcium antagonists interact with Cardiac Glycosides
Pierce, C.H., Consultant, 1/1/1986
When we should be measuring plasma concentrations of drugs
Pierce, C.H., Consultant, 1/1/1984
An Approach to Drug Interactions
Pierce, C.H., Consultant, 1/1/1982
Practical Aspects of Presenting Information to Practicing Physicians
Pierce, C.H., Journal of Clinical Pharmacology, 1/1/1981
Lactate metabolism during canine shock from hemorrhage, cardiac tamponade or endotoxin
Daniel, A.; Pierce, C.H.; MacLean, L.D. and Shizgal, H., Surgery, Gynecology and Obstetrics, 1/1/1976
Comments on the Management of Hypertension 1976
Pierce, C.H., Journal of the Medical Association of Alabama, 1/1/1976
Les mecanismes d'action d'un agent corticosteriodique synthetique dans le choc experimental
Pierce, C.H., L'Union Medicale du Canada, 1/1/1973
The enigma of shock
Pierce, C.H., Canadian Medical Association Journal, 1/1/1970
Theories of the production of shock: A review of their relevance to clinical practice
Bloch, J.H.; Dietzman, R.H.; Pierce, C.H. and Lillehei, R.C., British Journal of Anaesthesiology, 1/1/1966
Adrenergic Blocking agents in the treatment of shock
Bloch, J.H.; Pierce, C.H. and Lillehei, R.C., Annual Rev Medicine, 1/1/1966
Join now to see all

Books/Book Chapters

Steroids and Shock
Chapter: Mechanisms of the effectiveness of a synthetic corticosteroid like agent (Methylprednisolone) in controlled hypoperfusion induced shock.
Pierce, C.H.; Oshiro, G.; Briggs, B.T.; Kay, W.W. and Gutelius, J.R.Editors: T. Glen.University Park Press1974

Lectures

Working with IRBs and Regulators to prepare for Clinical Trial Audits
Bethesda, MD - 1/21/2009
PI Responsibility -The Scary Reality
Grand Rapids, MI - 1/15/2007
Why is Adverse Event reporting so essential
Hyderabad, India - 1/28/2006
What is the Informed Consent Process
Hyderabad, India - 1/28/2006
Research Subject Safety
Hyderabad, India - 1/28/2006
Human Research Subject Safety – Legal and ethical aspects.
Boston, MA - 1/22/2006
P.I. Responsibilities - The Reality
University of Cincinnati - 1/26/2005
The Role of Academia in the Drug Development Process
Montreal, Quebec, Canada - 1/25/2005
Responsibility: The key to Uncompromised Data
Hyderabad, India - 1/5/2005
How Compliance with GCP and the Regulations Protects Human Research Subjects
Philadelphia, PA - 1/25/2004
Principal Investigator Responsibilities - The Scary Reality
Ottawa, Ontario, Canada - 1/7/2004
The GCP’s of Clinical Research
Cincinnati Children’s Hospital Medical Center - 1/30/2003
Changing Face of Clinical Research
University of Cincinnati, College of Medicine - 1/23/2003
Health Needs in Kathmandu, Nepal - a World Away
Cincinnati Children’s Hospital Medical Center - 1/21/2003
Clinical Trail Design and Execution
Philadelphia, PA - 1/8/2003
The Clinical Investigators Responsibilities: The Reality
University of Cincinnati, College of Medicine - 1/8/2003
The Changing Face of Clinical Research
University of Cincinnati, Cincinnati, OH - 1/7/2003
Investigators Responsibilities in Clinical Research
University of Cincinnati, Cincinnati, OH - 1/30/2002
Clinical research through the eyes of the Ophthalmologist
Garmisch-Partenkirchen, Germany - 1/27/2002
Update on the management of Asthma
Patan Hospital and at the Nepal Medical College, Kathmandu, Nepal - 1/8/2002
What patients need to know to manage their asthma.
Queen Elizabeth Hospital, Bridgetown, Barbados - 1/5/2002
Methylprednisolone and phenoxybenzamine and experimental shock: cardiovascular dynamics and platelet function, Shock in Low and High Flow states.
Amsterdam, The Netherlands - 1/1/1982
The Importance of Adverse Event Reporting in Clinical Research
University of Cincinnati, College of Medicine
Join now to see all

Other

Guidelines for the Management of Hypertension 1976.
Pierce, C.H., Report of the Alabama Advisory and Coordinating Council on Hypertension
1/1/1976
Thesis: An Inquiry into the Nature of Circulatory Shock: Development and Use of an Experimental Model Utilizing Controlled Cardiac Tamponade.
Pierce CH, College of Graduate Studies
University of Saskatchewan - 1/1/1974
Thesis: Effects Upon Respiratory Function of a Meperidine Derivative Using a New Experimental Approach.
Pierce CH, Graduate School
University of Minnesota - 1/1/1961